文献速递临床免疫临床微生物

基于生物芯片的联合免疫检测用于莱姆病伯氏疏螺旋体血清学状态检测

A biochip-based combined immunoassay for detection of serological status of Borrelia burgdorferi in Lyme borreliosis.
PubMed 文献 · Clin Chim Acta · 2017-07-01

研究采用二硫代双(琥珀酰亚胺十一烷酸酯)修饰的金表面生物芯片,联合检测针对伯氏疏螺旋体多个抗原的免疫应答。56例神经莱姆病患者和114名健康人的样本分析显示,6种抗原的IgM或IgG抗体血清阳性率贡献了多重免疫生物芯片检测的总体灵敏度提升,患者血清6种抗原联合阳性率IgM为92.86%、IgG为91.07%。结论认为该联合生物芯片免疫检测有望替代ELISA,扩展对一组伯氏疏螺旋体抗原的感染抗体检测谱。

要点

  • 生物芯片可同时检测针对鞭毛蛋白、OspC、VlsE及3种VlsE IR6肽的抗体。
  • 患者血清6种抗原联合阳性率IgM为92.86%,IgG为91.07%。
  • 部分患者对3种VlsE IR6变异肽产生抗体应答,提示多菌株感染可能。

核心结论

  • 基于生物芯片的联合免疫检测可作为ELISA的潜在替代方法,扩展对一组伯氏疏螺旋体抗原的感染抗体检测谱。

研究设计与样本

  • 采用二硫代双(琥珀酰亚胺十一烷酸酯)修饰的金表面生物芯片作为联合免疫检测平台,并用傅里叶变换红外光谱验证修饰金表面的表面化学特征。
  • 检测样本来自56例神经莱姆病患者和114名健康个体。

主要发现

  • 生物芯片检测IgG抗体的检测限低至抗VlsE为0.39μg/ml,抗鞭毛蛋白和抗OspC分别为0.78μg/ml。
  • 针对6种抗原的IgM或IgG抗体血清阳性率贡献了多重免疫生物芯片检测的总体灵敏度提升。
  • 患者血清中6种抗原的联合阳性率IgM抗体为92.86%,IgG抗体为91.07%。
  • 部分患者对3种VlsE IR6变异肽产生抗体应答,提示莱姆病可能归因于一种或多种伯氏疏螺旋体菌株的多重感染。

临床怎么用

  • 生物芯片格式便于同时评估神经莱姆病患者血清中针对蛋白抗原和伯氏疏螺旋体IR6肽的IgM和IgG抗体,有助于检测扩展的血清学感染状态并更高效地制定治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dithiobis (succinimidyl undecanoate) modified gold surface biochip were used as a combined immunoassay platform for concurrently detecting immune responses to Borrelia burgdorferi (B. burgdorferi) sensu lato antigens, flagellin, outer surface protein C, variable major protein-like sequence proteins, and 3 VlsE protein IR6 peptides. The peptides represented intrinsic Borrelia genospecies: B. burgdorferi sensu stricto, B. garinii, and B. afzelii, respectively. METHODS: Fourier transform infrared spectroscopy was utilized to validate the surface chemical characteristics on the modified gold surface. RESULTS: The limits in detection of IgG antibody on the biochips were as little as 0.39μg/ml for anti-VlsE and 0.78μg/ml for anti-flagellin and anti-OspC, respectively. Samples from 56 neuroborreliosis (NB) patients and 114 healthy individuals were analyzed by the combined biochip. We found that the seroprevalences of IgM or IgG antibody against the 6 antigens were contributed to increased overall sensitivity by the multiplex immunobiochip assay. Serum combined positive rates of the 6 antigens in the patients were 92.86% for IgM antibody and 91.07% for IgG antibody. Part of the patients bore antibody responses against the 3 VlsE IR6 variant peptides, indicating that Lyme borreliosis would attribute to consequence of multiple infections by one or more Borrelia burgdorferi strains. Concurrent assessment for both IgM and IgG antibodies against the protein antigens and B. burgdorferi IR6 peptides in the sera of NB patients was beneficial from the biochip format, enabling detection of expanded serologic infection status and therapy strategy-making more efficiently. CONCLUSIONS: The combined biochip-based immunoassay, as a potential substitution of ELISA, provided a promising approach to extend the detection spectrum of infectious antibodies against a panel of Borrelia antigens.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Huang NL, Ye L, Lv H, et al. A biochip-based combined immunoassay for detection of serological status of Borrelia burgdorferi in Lyme borreliosis. Clin Chim Acta. 2017. PMID: 28676442. doi:10.1016/j.cca.2017.06.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。